HeartSciences Reminds Its Shareholders to Submit Their Vote at the Upcoming April 30, 2026, Annual Shareholders Meeting
Rhea-AI Summary
HeartSciences (Nasdaq: HSCS) reminds shareholders to submit voting instructions ahead of its virtual Annual Meeting on April 30, 2026 at 10:00 a.m. ET. Shareholders of record as of March 6, 2026 may vote by Internet at www.voteproxy.com or follow materials on the company proxy portal. Proxies must be submitted before 11:59 p.m. ET on April 29, 2026. For help, contact Advantage Proxy or review the definitive Proxy Statement filed on March 17, 2026 available through the company portal.
AI-generated analysis. Not financial advice.
Positive
- None.
Negative
- None.
News Market Reaction – HSCS
On the day this news was published, HSCS gained 0.51%, reflecting a mild positive market reaction. This price movement added approximately $34K to the company's valuation, bringing the market cap to $6.74M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Sector peers show mixed moves: RSLS up 29.8%, PAVM up 1.09%, SSKN down 11.31%, while HSCS is down 4.33%. With no peers in the momentum scanner and conflicting directions across the group, today’s weakness looks more stock-specific than sector-driven.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| 2026-03-25 | Product designation | Positive | +1.7% | MyoVista Insights received Epic Toolbox designation for ECG Management System category. |
| 2026-03-24 | Investor conference | Neutral | -1.6% | Company presented strategy and milestones at a virtual investor summit. |
| 2026-03-16 | Earnings update | Negative | -0.4% | Fiscal Q3 2026 showed no meaningful revenue but outlined cash and equity levels. |
| 2026-02-05 | Academic adoption | Positive | -3.8% | UWE adopted MyoVista platform and device as exclusive ECG technologies. |
| 2026-01-29 | Commercial partnership | Positive | +2.1% | Cibolo Health selected MyoVista Insights as endorsed ECG management platform. |
Operational and partnership news has often produced modest, mixed price reactions, with one clear divergence where a positive adoption announcement was followed by a decline.
Over the past few months, HeartSciences has focused on commercializing its AI‑driven ECG platforms. Key milestones include Cibolo Rural Health Networks endorsing MyoVista Insights for 123 hospitals on Jan 29, 2026, UWE adopting the platform and device for an ECG reference center on Feb 5, 2026, and Epic Toolbox designation on Mar 25, 2026. Financially, fiscal Q3 2026 results highlighted no meaningful revenue but cash of $3.4M. The current proxy reminder ties directly to ongoing governance steps around equity incentives and board elections.
Market Pulse Summary
This announcement centers on the upcoming April 30, 2026 virtual Annual Meeting and encourages shareholders of record as of March 6, 2026 to vote. It connects directly to earlier proxy materials seeking approval for expanding the 2023 Equity Incentive Plan and other governance items. In light of past filings highlighting limited revenue, ongoing losses, and a cash balance of $3.4M, investors may focus on how board and equity decisions support long-term funding and commercialization of HeartSciences’ AI‑ECG technologies.
Key Terms
series c preferred stock financial
proxy statement regulatory
schedule 14a regulatory
equity incentive plan financial
certificate of formation regulatory
restricted stock units financial
regulation a offering regulatory
10-q regulatory
AI-generated analysis. Not financial advice.
Southlake, TX, April 14, 2026 (GLOBE NEWSWIRE) -- HeartSciences Inc. (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”) a healthcare information technology (“HIT”) company focused on advancing electrocardiography (“ECG” or “EKG”) through the integration of artificial intelligence (“AI”), would like to remind its shareholders to vote ahead of its upcoming Annual Meeting of Shareholders (the “Annual Meeting”) which will be held virtually on Thursday, April 30, 2026, at 10:00 a.m. Eastern Time. All shareholders of record of HeartSciences’ outstanding shares of common stock and Series C preferred stock at the close of business on March 6, 2026, are entitled to participate and vote at the Annual Meeting.
HeartSciences encourages all shareholders vote their proxy card, regardless of how many shares they own.
HeartSciences’ shareholders of record can vote over the Internet, by going to the website of HeartSciences’ tabulator, Equiniti, at www.voteproxy.com. Please have your proxy card in hand when you access the website and follow the instructions to vote your shares. Shareholders of record must submit their Internet proxy before 11:59 p.m., Eastern Time, on April 29, 2026, the day prior to the Annual Meeting, for their proxy to be valid and their vote to count.
For assistance with voting your shares, please contact Advantage Proxy, Inc. toll-free at 1-877-870-8565 or by e-mail at ksmith@advantageproxy.com.
HeartSciences strongly encourages all of its shareholders to read the Company’s definitive Proxy Statement on Schedule 14A, filed with the U.S. Securities and Exchange Commission on March 17, 2026, and other proxy materials relating to the Annual Meeting, which are available free of charge at https://www.astproxyportal.com/ast/27913/ and following the on-screen instructions.
About HeartSciences
HeartSciences is a healthcare information technology (“HIT”) company advancing the use of ECG/EKGs through the integration of artificial intelligence (“AI”). The Company’s MyoVista Insights™ Platform is a device-agnostic, next-generation ECG management system designed to improve clinical efficiency and decision-making. Its MyoVista wavECG device is designed to deliver conventional ECG functionality while supporting on-device AI-enabled solutions.
For more information, please visit: https://www.heartsciences.com. X: @HeartSciences
Safe Harbor Statement
This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements are made under the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and are relating to the Company's future financial and operating performance. All statements, other than statements of historical facts, included herein are "forward-looking statements" including, among other things, statements about HeartSciences' beliefs and expectations. These statements are based on current expectations, assumptions and uncertainties involving judgments about, among other things, future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond the Company's control. The expectations reflected in these forward-looking statements involve significant assumptions, risks and uncertainties, and these expectations may prove to be incorrect. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Potential risks and uncertainties include, but are not limited to, risks discussed in HeartSciences' Annual Report on Form 10-K for the fiscal year ended April 30, 2025, filed with the U.S. Securities and Exchange Commission (the "SEC") on July 24, 2025, HeartSciences’ Quarterly Report on Form 10-Q for the fiscal quarter ended January 31, 2026 filed with the SEC on March 16, 2026, and in HeartSciences' other filings with the SEC at www.sec.gov. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.
Investor Relations:
Integrous Communications
Mark Komonoski, Partner
Phone: 877 255 8483
Email: mkomonoski@integcom.us
Media Contact:
HeartSciences
Gene Gephart
Phone: +1 682 244 2578 Ext. 2024
Email: info@heartsciences.com
